61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
ADMA Biologics Inc
Closed
Sector Healthcare
16.89 2.99
Overview
Share price change
24h
Min
16.06
Max
16.98
Income | 3.8M 36M |
|---|---|
Sales | 13M 120M |
P/E Sector Avg | 62.066 59.362 |
EPS | 0.15 |
Profit margin | 29.964 |
EBITDA | -103K 42M |
Next Earnings | 26 Feb 2025 |
|---|
Market Cap | 12M 3.8B |
|---|---|
Previous open | 13.9 |
Previous close | 16.89 |
News Sentiment
By Acuity
59%
41%
328 / 393 Healthcare
Technical Score
By Trading Central
Confidence
Strong Bullish Evidence
ADMA Biologics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
ADMA Biologics Inc Forecast
Sentiment
By Acuity
328 / 393 Healthcare
News Sentiment
Bearish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About ADMA Biologics Inc
ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include ADMA BioManufacturing and Plasma Collection Centers. The Company’s ADMA BioManufacturing segment reflects its immune globulin manufacturing and development operations in Florida. The Plasma Collection Centers segment consists of approximately three plasma collection facilities. Its products include BIVIGAM, ASCENIV and Nabi-HB. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons.
